Investor Presentaiton
Financial Results for Q4 FY2022
Marketing Status of ORGOVYX®
Approx. 5,000 new patients started treatment
with ORGOVYX® in Q4 FY2022
(19% growth vs. Q3 FY2022)
+19%
31,000
26,000
22,000
18,000
14,500
11,000
8,000
4,500
■The market for androgen deprivation therapy targeted
by ORGOVYX® is over 200 billion yen/year (gross
conversion), and recently expanded by approx. 20%
annually*
■Established broad health plan coverage (Percentage
of coverage obtained as of April 2023: total of
Medicare Part D lives was approx. 100%, total of
commercial lives was >90%)
■ Gathering new evidence for further potential utility
(Use in combination therapy and cardiovascular event
Q1
Q2
Q3
FY2021 FY2021 FY2021 FY2021 FY2022 FY2022 FY2022
Q4
Q1
Q2
Q3
Q4
FY2022
risks)
Estimated Cumulative Patients Treated with ORGOVYX®
(includes patients on free and commercial drug, excludes patients utilizing product samples)
*Source IQVIA
*NSP sales for RELUGOLIX, DEGARELIX, GOSERELIN,
LEUPROLIDE, and TRIPTORELIN for the 12 months ended Feb.
2023 were $1,612M (130yen/$), which reflects a 21% growth vs the
12 months ended Feb. 2022View entire presentation